MyCode participants with a P/LP BRCA1/2 variant were significantly more likely than participants without a BRCA1/2 variant to have a history of breast cancer (odds ratio, 5.95) or ovarian cancer (odds ratio, 18.3) (Manickam et al., 2018). This evidence concerns the gene BRCA1 and ovarian carcinoma.